Abstract 207P
Background
Diabetes mellitus is considered as a potential risk factor for breast cancer, yet the relationship between diabetic background retinopathy (DBR) and breast cancer remains uncertain. This study leverages mendelian randomization (MR) to explore the genetic link between diabetic background retinopathy (DBR) and estrogen receptor-positive (ER+) breast cancer, highlighting the connection with diabetes-related conditions.
Methods
We acquired summary data from a genome-wide association study (GWAS) concerning DBR in the European population, with a focus on their relationship with ER+ breast cancer. We performed two-sample MR analysis with multiple approaches to evaluate the potential causal associations between DBR and ER+ breast cancer. Pleiotropy and Cochran's Q tests were utilized to determine horizontal pleiotropy and heterogeneity.
Results
Of the 205,044 participants (2,026 DBR cases) from FinnGenn, we identified 8 single nucleotide polymorphisms (SNPs) associated with the risk of ER+ breast cancer (69,501 ER+ breast cancer cases from iCOGS). The MR analysis showed a suggestive association between DBR susceptibility and ER+ breast cancer (weight median odds ratio [OR]: 0.971, 95% confidence interval [CI]: 0.955-0.987, P = 0.0006; simple mode OR: 0.964, P = 0.043; weight mode OR: 0.971, P = 0.015). The effect size estimate (β) for weight median model was -0.0294, indicating a 2.94% decrease in the odds of ER+ breast cancer per unit increase in genetically predicted DBR. Sensitivity analyses are consistent with the results, manifesting that our findings were convincing and robust.
Conclusions
These finding suggests that a potential inverse relationship between DBR and the risk of ER+ breast cancer. These findings could significantly impact screening and prevention strategies for diabetic populations, emphasizing the need for further research into this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1182P - Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform
Presenter: Praful Ravi
Session: Poster session 09
1183P - Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk
Presenter: Christina Dilaveri
Session: Poster session 09
1184P - Early real-world experience with positive multi-cancer early detection (MCED) test cases and negative initial diagnostic work-up
Presenter: Candace Westgate
Session: Poster session 09
1185P - Clinical applications of a novel blood-based fragmentomics assay for lung cancer detection
Presenter: Marc Siegel
Session: Poster session 09
1186P - SmartCS-LPLLM: Enhancing early cancer detection through ctDNA methylation analysis leveraging large language models
Presenter: Li Chao
Session: Poster session 09
1187P - Molecular diagnosis of lung cancer via ctDNA and ctRNA detection on bronchoscopic fluid specimens from 31 patients: A retrospective analysis
Presenter: Vincent Fallet
Session: Poster session 09
1188P - Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes
Presenter: Sana Raoof
Session: Poster session 09
1189P - Cancer genome interpreter: A data-driven tool for tumor mutation interpretation
Presenter: Santiago Demajo
Session: Poster session 09
1190P - Circulating tumor DNA from the tumor-draining pulmonary vein as a biomarker in resected non-small cell lung cancer
Presenter: Raphael Werner
Session: Poster session 09
1191P - Efficient lung cancer stage prediction and outcome informatics with Bayesian deep learning and MCMC method
Presenter: Maria Gkotzamanidou
Session: Poster session 09